Market cap
₹5 Cr
Revenue (TTM)
₹24 Cr
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
5 | 35,497 | 29,798 | 16,589 | 15,507 |
Revenue (₹ Cr) |
24 | 9,683 | 2,372 | 2,590 | 1,108 |
Net Profit (₹ Cr) |
0.07 | 1,018.97 | 497.77 | 603.02 | 270.18 |
Net Margin (%) |
0.29 | 10.47 | 20.72 | 22.63 | 23.29 |
RoE (%) |
0.18 | 21.30 | 28.49 | 19.61 | 14.45 |
Price to Earnings |
-- | 35.10 | 59.86 | 27.51 | 56.31 |
Price-To-Book |
0.12 | 6.77 | 14.74 | 4.76 | 7.48 |
Income Statement (₹ Cr)
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
24.36 | 7,896.00 | 1,476.84 | 2,386.88 | 1,200.09 |
|
Total Income
|
24.68 | 7,968.78 | 1,497.35 | 2,421.45 | 1,244.53 |
|
Total Expenditure
|
24.57 | 6,427.14 | 1,153.58 | 1,704.30 | 693.24 |
|
EBITDA
|
-0.21 | 1,468.85 | 323.26 | 682.58 | 506.84 |
|
Depreciation
|
0.00 | 384.13 | 65.55 | 60.61 | 54.37 |
|
EBIT
|
-0.21 | 1,084.73 | 257.71 | 621.98 | 452.47 |
|
Interest
|
-- | 175.78 | 8.30 | 2.41 | 1.04 |
|
Other Income
|
0.32 | 72.79 | 20.51 | 34.57 | 44.45 |
|
Exceptional Items
|
-- | -10.38 | 76.40 | -- | -- |
|
Profit before Tax
|
0.11 | 971.35 | 346.33 | 654.13 | 494.55 |
|
Provision for Tax
|
0.04 | 263.88 | 86.22 | 168.50 | 122.91 |
|
Profit after Tax
|
0.07 | 707.47 | 260.11 | 485.63 | 371.64 |
Liabilities (₹ Cr)
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
39.21 | 4,446.19 | 1,524.81 | 2,817.37 | 1,812.72 |
|
Minority Interest
|
-- | 195.37 | -- | -- | -- |
|
Non-Current Liabilities
|
-- | 811.91 | 189.39 | 466.05 | 37.47 |
|
Current Liabilities
|
5.04 | 2,668.27 | 465.69 | 470.16 | 184.06 |
|
Total Liabilities
|
44.25 | 8,121.73 | 2,179.88 | 3,753.59 | 2,034.25 |
Assets (₹ Cr)
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.01 | 3,565.87 | 1,040.38 | 1,418.43 | 899.01 |
|
Current Assets
|
44.25 | 4,555.86 | 1,139.50 | 2,335.16 | 1,135.24 |
|
Total Assets
|
44.25 | 8,121.73 | 2,179.88 | 3,753.59 | 2,034.25 |
|
Total Debt*
|
0.23 | 731.70 | 136.01 | 0.00 | 0.38 |
|
Net Current Assets
|
39.20 | 1,887.59 | 673.81 | 1,865.00 | 951.18 |
|
Contingent Liabilities
|
-- | 393.94 | 8.97 | 4.82 | 3.91 |
Cashflow (₹ Cr)
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.01 | 851.71 | 317.40 | 391.52 | 244.52 |
|
Cash Flow from Investing Activities
|
0.00 | -94.00 | -298.16 | -615.65 | -159.99 |
|
Cash from Financing Activities
|
-0.03 | -813.96 | 24.96 | -6.23 | -98.77 |
|
Net Cash Inflow / Outflow
|
-0.04 | -56.25 | 44.21 | -230.35 | -14.24 |
Ratios
Profitability Ratios
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
0.27 | 22.49 | 23.45 | 25.50 | 29.62 |
|
ROE (%)
|
0.18 | 19.19 | 18.54 | 18.94 | 22.26 |
|
ROA (%)
|
0.16 | 8.94 | 12.97 | 13.34 | 19.90 |
|
EBIT Margin (%)
|
0.45 | 19.52 | 23.28 | 30.05 | 45.94 |
|
Net Margin (%)
|
0.29 | 8.88 | 17.37 | 20.06 | 29.86 |
|
Cash Profit Margin (%)
|
0.30 | 13.61 | 22.05 | 22.79 | 35.50 |
Growth Ratios
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
270.47 | 18.59 | -5.24 | 4.54 | 18.01 |
|
EBIT Growth (%)
|
-87.94 | 19.81 | -27.65 | 4.50 | 18.31 |
|
Net Profit Growth (%)
|
-89.34 | 34.10 | -13.32 | 3.13 | 20.62 |
|
EPS Growth (%)
|
-89.35 | 30.75 | -13.32 | 3.12 | 20.62 |
|
Book Value Growth (%)
|
0.18 | 50.94 | 18.89 | 20.94 | 18.74 |
Valuation Ratios
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
211.44 | 29.84 | 59.57 | 27.24 | 47.19 |
|
Price / Book Value
|
0.38 | 4.58 | 10.17 | 4.71 | 9.67 |
|
Dividend Yield (%)
|
0.00 | 0.28 | 0.10 | 0.46 | 0.64 |
|
EV/EBITDA
|
137.32 | 13.55 | 44.72 | 18.35 | 31.81 |
|
Market Cap (₹ Cr)
|
15.00 | 20,327.45 | 15,494.53 | 13,228.83 | 17,537.35 |
Solvency Ratios
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | 0.17 | 0.09 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
0.01 | 0.11 | -- | -- | 0.00 |
|
Current Ratio
|
8.77 | 1.71 | 2.45 | 4.97 | 6.17 |
|
Quick Ratio
|
8.30 | 0.98 | 1.62 | 3.53 | 4.87 |
|
Interest Coverage
|
-- | 6.53 | 42.74 | 271.97 | 475.76 |
Operating Efficiency Ratios
| Patron Exim | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
25.07 | 25.36 | 21.38 | 40.63 | 43.47 |
|
Asset Turnover
|
0.54 | 1.01 | 0.74 | 0.66 | 0.64 |
|
Receivable days
|
121.64 | 87.83 | 85.17 | 132.12 | 132.49 |
|
Inventory Days
|
35.63 | 78.64 | 90.97 | 102.08 | 68.07 |
|
Payable days
|
73.02 | 174.97 | 137.94 | 133.54 | 123.94 |
|
Cash Conversion Cycle
|
84.25 | -8.50 | 38.21 | 100.66 | 76.63 |